Patients with recurrent advanced-stage and/or metastatic cervical cancer typically have a poor prognosis with limited treatment options available. Now, data from the phase III innovaTV 301 trial demonstrate the efficacy of the tissue factor-targeted antibody–drug conjugate tisotumab vedotin in this setting.

A total of 502 patients with advanced-stage and/or metastatic cervical cancer who previously received 1 (62.8%) or 2 (36.8%) lines of therapy were randomly assigned (1:1) to receive tisotumab vedotin versus investigator’s choice of chemotherapy (including topotecan, vinorelbine, gemcitabine, irinotecan or pemetrexed). Overall survival (OS) was the primary end point.

复发性晚期和/或转移性宫颈癌患者通常预后不良，可用的治疗选择有限。现在，来自 III 期 innovaTV 301 试验的数据证明了组织因子靶向抗体药物偶联物 tisotumab vedotin 在此情况下的功效。

共有 502 名既往接受过 1 线 (62.8%) 或 2 线 (36.8%) 治疗的晚期和/或转移性宫颈癌患者被随机分配 (1:1) 接受 tisotumab vedotin 治疗组与研究者选择的化疗组（包括拓扑替康、长春瑞滨、吉西他滨、伊立替康或培美曲塞）。总生存期（OS）是主要终点。